At a glance: 5-Amino-1MQ is a lab-made small molecule (not a peptide) that blocks an enzyme called NNMT. In mice it reduced body fat and improved muscle function in aging animals. No human clinical trials have been published, it is not FDA-approved, and there is no established human dose or long-term safety data.
What is 5-Amino-1MQ?
5-Amino-1MQ (short for 5-amino-1-methylquinolinium) is a small molecule developed by researchers at the University of Texas Medical Branch to block nicotinamide N-methyltransferase (NNMT). It is often sold and discussed alongside peptides, but chemically it is not a peptide: it is a compact, ring-shaped compound designed to enter cells easily.
NNMT is an enzyme found mainly in fat tissue and the liver. Research has found higher NNMT levels in the fat tissue of obese and insulin-resistant animals and people, which led scientists to ask whether turning the enzyme down could change how fat cells store and burn energy.
How does 5-Amino-1MQ work?
NNMT attaches a methyl group to nicotinamide (a form of vitamin B3). That reaction uses up two things cells rely on: nicotinamide, a building block for NAD+, the molecule cells need to turn fuel into energy, and SAM, the body's main methyl-group donor. The by-product, 1-methylnicotinamide, is excreted.
The theory is that blocking NNMT leaves more of those resources available inside fat cells. In a landmark 2014 mouse study, reducing NNMT in fat and liver tissue raised energy expenditure and protected mice from diet-induced obesity. 5-Amino-1MQ was designed to produce a similar effect with a drug instead of genetic knockdown.
- Blocks NNMT, so less nicotinamide and SAM are consumed
- Supports NAD+ levels in fat cells, which may increase energy use
- Shrinks fat cells in animal models without reducing food intake
These mechanisms come from cell and animal experiments. They have not been confirmed in human studies.
What the research shows so far
All published efficacy data on 5-Amino-1MQ come from mice and cell cultures. The main findings:
| Study | Model | Main finding |
|---|---|---|
| Neelakantan et al., 2018 | Obese mice on a high-fat diet | Short-term treatment lowered body weight and white fat mass, shrank fat cells, and reduced cholesterol, with no change in food intake |
| Neelakantan et al., 2019 | Aged mice with muscle injury | Activated aged muscle stem cells, producing larger regenerating muscle fibers and stronger contraction |
| Sampson et al., 2021 | Obese mice on a reduced-calorie diet | Adding NNMT inhibition brought body weight and fat closer to lean-mouse levels than diet alone |
| Dimet-Wiley et al., 2024 | Aged female mice, with or without exercise | Eight weeks of treatment raised grip strength about 40% in sedentary mice; combined with exercise the gain was larger, and fat stored inside muscle fell |
Animal results do not reliably predict effects or safety in people.
Why it gets attention
- Fat loss without appetite suppression in mice, unlike most weight-loss drugs
- Possible muscle benefits in aging animals, a rare combination with fat loss
- Interest in NAD+ and healthy aging, a popular research area
- Heavy online marketing by research-chemical sellers and some clinics, often ahead of the evidence
How it has been given in studies
In the published mouse studies, 5-Amino-1MQ was given by daily injection under the skin at weight-based amounts for days to weeks. Online sellers offer capsules and vials labeled "research use only," but those products have not been tested in human trials, and no human dose has been established. This page does not provide dosing or administration guidance.
What we don't know yet
- Whether it works in people at all, or at what dose
- Long-term safety, including effects on the liver, where NNMT is also active
- Interactions with other medications or supplements
- How results in mice would translate to humans, which they often don't
What about side effects?
There is no human safety data. The short mouse studies did not report obvious toxicity at the amounts tested, but that cannot establish safety in people. Because NNMT also plays roles in the liver and in methylation, long-term blockade could have effects that short animal studies would miss.
Product quality is a separate risk. Research-use-only compounds are not regulated for purity, strength, or sterility, and independent testing of online products has repeatedly found mislabeled or contaminated items.
Regulatory status
5-Amino-1MQ is not an FDA-approved drug for any condition, and no human clinical trials have been published. Some clinics offer it through compounding pharmacies, but compounded drugs are not FDA-reviewed for safety or effectiveness, and whether a substance may legally be compounded depends on FDA bulk-substance rules. Products sold online as "research chemicals" are not intended for human use.
How it compares to other body-composition compounds
| Compound | Type | How it acts | Human evidence | US status |
|---|---|---|---|---|
| 5-Amino-1MQ | Small molecule | Blocks NNMT in fat cells | None published | Not approved |
| Semaglutide | Peptide (GLP-1 agonist) | Reduces appetite, slows digestion | Large randomized trials | FDA-approved |
| Tirzepatide | Peptide (GIP/GLP-1 agonist) | Reduces appetite, improves insulin response | Large randomized trials | FDA-approved |
| Tesamorelin | Peptide (GHRH analog) | Raises growth hormone to reduce belly fat | Randomized trials in HIV-associated fat gain | FDA-approved for that use |
Approved medicines have far more human data than 5-Amino-1MQ. Their use still requires a prescriber.
The bottom line
5-Amino-1MQ is a scientifically interesting compound with encouraging early results in mice, especially for fat loss and age-related muscle decline. But it has not been tested in published human trials, has no established dose or safety profile, and is not approved for any use. Anyone interested in weight or body-composition treatment should talk with a licensed clinician about options backed by human evidence.
Frequently asked questions
What is 5-Amino-1MQ?
A small molecule, not a peptide, that blocks NNMT, an enzyme involved in how fat cells use energy.
How is 5-Amino-1MQ taken?
Oral or injected in animal studies.
Is 5-Amino-1MQ FDA approved?
Not approved.
That means no regulator has reviewed its safety, effectiveness or manufacturing quality for this use.
What has research shown about 5-Amino-1MQ?
- Fat mass and body weight in mice on high-fat diets.
- Fat cell metabolism in lab studies.
What side effects have been reported?
- Not characterised in humans
Serious or less common risks are listed in the Side Effects section above.
What is still unknown about its safety?
Most of it. 5-Amino-1MQ has not been through the trials that establish long-term safety in people, and products sold online are made by unregulated labs. Independent testing of online peptides has repeatedly found contents that do not match the label.
References
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508:258–262. View source
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141–152. View source
- Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019;163:481–492. View source
- Sampson CM, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Scientific Reports. 2021;11. View source
- Dimet-Wiley AL, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Scientific Reports. 2024;14:15554. View source